**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74720

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Complications of chronic pancreatitis prior to and following surgical treatment: A proposal for classification**

Murruste M *et al*. Complications of chronic pancreatitis

Marko Murruste, Ülle Kirsimägi, Karri Kase, Tatjana Veršinina, Peep Talving, Urmas Lepner

**Marko Murruste, Ülle Kirsimägi, Karri Kase, Tatjana Veršinina, Urmas Lepner,** Department of Surgery, Tartu University Hospital, Tartu 50406, Estonia

**Peep Talving,** Department of Surgery, Board, North Estonia Medical Centre, Tallinn 13419, Estonia

**Author contributions:** Murruste M, Kirsimägi Ü, Kase K, Veršinina T, Talving P, and Lepner U designed the study; Murruste M, Kirsimägi Ü, Kase K, and Veršinina T performed the study; Murruste M and Kirsimägi Ü produced the statistics and wrote the paper.

**Corresponding author: Marko Murruste, MD, Doctor, Surgeon,** Department of Surgery, Tartu University Hospital, 8 Puusepa Str, Tartu 50406, Estonia. marko.murruste@kliinikum.ee

**Received:** January 3, 2022

**Revised:** March 22, 2022

**Accepted: June 13, 2022**

**Published online:**

**Abstract**

BACKGROUND

Chronic pancreatitis (CP) is a long-lasting disease frequently associated with complications for which there is no comprehensive pathophysiological classification.

AIM

The aims of this study were to: Propose a pathophysiological classification of the complications of CP; evaluate their prevalence in a surgical cohort prior to, and following surgical management; and assess the impact of the surgical treatment on the occurrence of new complications of CP during follow-up. We hypothesized that optimal surgical treatment can resolve existing complications and reduce the risk of new complications, with the exclusion of pancreatic insufficiency. The primary outcomes were prevalence of complications of CP at baseline (prior to surgical treatment) and occurrence of new complications during follow-up.

METHODS

After institutional review board approval, a prospective observational cohort study with long-term follow-up (up to 20.4 years) was conducted. All consecutive single-center adult patients (≥ 18 years of age) with CP according to the criteria of the American Pancreas Association subjected to surgical management between 1997 and 2021, were included. The prevalence of CP complications evaluated, according to the proposed classification, in a surgical cohort of 166 patients. Development of the pathophysiological classification was based on a literature review on the clinical presentation, course, and complications of CP, as well a review of previous classification systems of CP.

RESULTS

We distinguished four groups of complications: Pancreatic duct complications, peripancreatic complications, pancreatic hemorrhages, and pancreatic insufficiency (exocrine and endocrine). Their baseline prevalence was 20.5%, 23.5%, 10.2%, 31.3%, and 27.1%, respectively. Surgical treatment was highly effective in avoiding new complications in the first and third groups. In the group of peripancreatic complications, the 15-year Kaplan-Meier prevalence of new complications was 12.1%. The prevalence of pancreatic exocrine and endocrine insufficiency increased during follow-up, being 66.4% and 47.1%, respectively, at 15 years following surgery. Pancreatoduodenal resection resulted optimal results in avoiding new peripancreatic complications, but was associated with the highest rate of pancreatic exocrine insufficiency.

CONCLUSION

The proposed complication classification improves the understanding of CP. It could be beneficial for clinical decision making, as it provides an opportunity for more comprehensive judgement on patient’s needs on the one hand, and on the pros and cons of the treatment under consideration, on the other. The presence of complications of CP and the risk of development of new ones should be among the main determinants of surgical choice.

**Key Words:** Chronic pancreatitis; Complications; Classification; Pathophysiology; Surgical treatment

Murruste M, Kirsimägi Ü, Kase K, Veršinina T, Talving P, Lepner U. Complications of chronic pancreatitis prior to and following surgical treatment: A proposal for classification. *World J Clin Cases* 2022; In press

**Core Tip:** Chronic pancreatitis is frequently associated with complications for which there exists no classification. This study proposes a pathophysiological classification of the complications of chronic pancreatitis (CP) and reports their prevalence in a surgical cohort. We distinguished four groups of complications: Pancreatic duct complications, peripancreatic complications, pancreatic hemorrhages, and pancreatic insufficiency. We believe the proposed classification improves the understanding of CP and could be beneficial for clinical decision making, as it provides an opportunity for more comprehensive judgement on patient’s needs on the one hand, and on the pros and cons of the treatment under consideration, on the other.

**INTRODUCTION**

Chronic pancreatitis (CP) is a benign chronic inflammatory damage of the pancreatic gland, with common morphologic features including the triad of fibrosis, loss of the acinar tissue, and ductal changes with highly heterogeneous clinical presentations[1]. The disease may present either with a single, most frequent symptom of CP, *i.e.* chronic abdominal pain, or as a combination of symptoms encompassing pain, symptoms of loss of pancreatic function and symptoms of local complications of peripancreatic organs[2,3]. Behind the myriad of symptoms, there can be distinct morphological changes of the pancreatic gland and surrounding structures[4]. During the course of the disease, most of the patients suffer from some, or even many, of the complications of CP. Although surgical treatment is usually indicated in the case of intractable abdominal pain, in up to one-third of cases, surgery is indicated mainly due to local complications of CP[5]. Previous systematic reviews have noted that surgery is the best option for the treatment of chronic pancreatic pain, and is effective in the treatment of most complications of CP[6,7]. However, the impact of surgical treatment on occurrence of new complications of CP is not sufficiently evaluated. Furthermore, it would be important to assess which pathophysiological pathways of the complications of CP are most effectively treated surgically and which surgical methods are most effective. A prerequisite for this kind analysis is a pathophysiological classification of the complications of CP. Although the surgical literature offers high-quality descriptions of all known complications of CP and lists of them[8], there are yet no pathophysiological classifications of complications available.

In this study, we proposed this classification comprising the major clinical problems seen in patients with CP. We reported data about the prevalence of the complications in a surgically treated cohort of 166 patients as well as data about the occurrence of new complications of CP during the postoperative period.

**MATERIALS AND METHODS**

***Patients***

After institutional review board approval, a prospective observational cohort study with long-term follow-up (up to 20.4 years) was conducted. All consecutive single-center adult patients (≥ 18 years of age) with CP according to the criteria of the American Pancreas Association subjected to surgical management between 1997 and 2021, were included[9]. All patients gave their informed consent.

***Aims and outcome***

The aims of this study were to: Propose a classification of complications of CP based on the predominant pathophysiological mechanism and clinical presentation, evaluate the prevalence of complications of CP in a surgical cohort; and assess the impact of surgical treatment on the occurrence of new complications of CP during follow-up. We hypothesized that optimal surgical treatment can resolve existing complications and reduce the risk for new complications, with the exclusion of pancreatic insufficiency. The primary outcomes were prevalence of complications of CP at baseline (prior to surgical treatment) and occurrence of new complications during follow-up.

***Baseline and follow-up data***

Data about the patients’ demographics, indications for surgical treatment, and operative characteristics, as well as about local changes in the pancreatic gland were recorded prospectively after surgical treatment; additional data were retrieved from surgical case files and computed tomography (CT) scan descriptions. CT scan was routinely used in all cases. CP-associated data comprised duration and etiology of CP, data on pancreatic function, and local changes in the pancreatic gland. All data about complications of CP occurring before surgical treatment and during follow-up were collected. The patients were followed up from surgical treatment until the end of the study (August 31, 2021) or until death. No patients were lost during follow-up. Additional health- related data were obtained from hospital case files, from the National Electronic Health Database (E-health), and from general practitioners’ reports. E-health contains full information about in- and outpatient visits.

***Statistics***

Collected data were entered in a computerized database (Microsoft Access 2016, Microsoft Inc., Redmond, WA, United States). The main characteristics are presented as the mean ± SD or the median with interquartile range as appropriate. The prevalence of the complications of CP was assessed according to the proposed pathophysiological classification. Complication-free survival was characterized using the Kaplan-Meier method. The impact of surgical treatment on the occurrence of new complications during the postoperative period was assessed using the Kaplan-Meier method. The log-rank test was deployed to assess differences between the Kaplan-Meier curves. The software package Statistica version 13.3 (TIBCO Software, Palo Alto, CA, United States) was utilized for statistical calculations.

***Classification of complications of CP***

All pathological changes of CP were divided into three groups: Cardinal histological features of CP (microscopic changes), common anatomical changes seen in pancreatic imaging (macroscopic changes), and complications of CP.

**Histological features of CP–microscopic changes:** The main microscopic features, or so-called ‘triad of CP’, were defined by Klöppel[10] and Kleeff *et al*[11] as progressive irreversible loss of acinar tissue (atrophy), its replacement by fibrotic tissue, and changes of the pancreatic duct (PD, atrophic epithelium, protein plugs, distortions)[10,11]. However, clinical decision making usually has to be done without histological confirmation of CP. Given the potential for complications, pancreatic biopsy is not indicated for proving the diagnosis of CP. Thus, diagnosis is usually based on a typical history of CP and radiological finding. The only indication for pancreatic biopsy is in suspected malignancy or autoimmune pancreatitis[11].

**Common anatomical changes in pancreatic imaging–macroscopic changes:** The second group of pathological changes was defined as macroscopic abnormalities of the pancreatic gland and ducts that are commonly seen in pancreatic imaging. Four distinguished findings of CP were noted: Pancreatic calcifications[12], pancreatic ductal changes (dilatations and strictures of PD; dilated PD was defined as PD with a diameter ≥ 3.5 mm); pancreatic head enlargement (chronic inflammatory mass or pancreatic pseudotumor, defined as antero-posterior diameter of the pancreatic head > 35 mm)[13], and pancreatic atrophy (defined as a thickness of the pancreas ≤ 20 mm in the left vertebral margin)[14]. Although the magnitude of these changes may significantly vary, none of them (if asymptomatic) is an indication for any type of treatment, as there is currently no known therapy to reverse or stop the progression of chronic inflammation in the pancreatic gland. Clinical management primarily consists of screening for and treating complications.

**Complications of CP–changes with clinical relevance:** The third group of pathological changes of CP was titled ‘complications of CP’ due to association with more or less severe clinical signs and symptoms. According to predominant pathophysiology and associated clinical presentation, we distinguished four groups of complications: PD complications, peripancreatic complications, pancreatic hemorrhages, and pancreatic insufficiency (Figure 1). Figure 2 shows a schematic illustration of the main complications of CP.

***Group I: PD complications***

Main pathophysiology: This particular group consists of complications caused by obstruction of PD by calcifications, protein plugs and/or periductal fibrosis, followed by intraductal hypertension and disruption of the main PD or its branches[15,16]. PD disruption results in the development of pancreatic pseudocysts (PPC) or leakage of pancreatic secretions, and hence to the development of various types of pancreatic fistulas (PF)[17]. The source of PF can be leakage directly from a rupture of the PD, or more frequently, leakage from a ruptured PPC. In the case of pancreatic ascites, pancreatic secretions leak into the abdominal cavity. In the case of pancreaticopleural fistula, pancreatic secretion flows through the retroperitoneum *via* the area of least resistance into the pleural cavity, usually through the esophageal hiatus. The tract of fistula directly through the diaphragm has also been described[18].

Prevalence and main clinical problems: PPC are common complications of CP, with a reported prevalence as high as 10%-40%[19,20]. Most of the small PPC are asymptomatic and do not need any treatment. Clinical presentation tends to occur if some of the secondary complications of PPC, such as bleeding, rupture or infection, evolve[21]. Additionally, large PPC can alone, through compression or in conjunction with underlying CP, lead to obstruction of the lumen of adjacent organs (biliary tract, gastric outlet, and peripacreatic veins)[22]. All secondary complications of PPC can occur throughout the clinical course, and if present, usually do need active treatment[20]. Although the complications of PPC and related clinical presentation can be diverse and dependent on the localization and size of PPC, patients most frequently present with abdominal pain[23].

Despite the fact that PF are relatively rare, the gross prevalence of various types of PF is reportedly as high as 3.5%[24,25]. Pancreaticoperitoneal fistulas with a prevalence of 2% (leading to pancreatic ascites) and pancreaticopleural fistulas with a prevalence of 1% (leading to pancreatic pleural effusions) are more common[26,27]. Both of them need PD decompression; in most cases endoscopic stenting of PD is sufficient[19]. Pancreaticogastric or intestinal fistulas, which may appear as symptomless findings in endoscopic evaluation, are rarer. Pancreaticocutaneous fistulas are usually the consequence of previous percutaneous drainages of PPC or pancreatic fluid collections, and may lead to significant loss of pancreatic juice and local skin problems. Pancreaticopericardial fistulas (leading to pancreatic pericardial effusion) and pancreaticoportal fistulas (leading usually to portal thrombosis with following consequences) are casuistic[28,29].

***Group II: Peripancreatic complications***

Main pathophysiology: The second group of complications comprises obstructive complications of organs adjacent to the pancreas (biliary tract, duodenum and major peripancreatic veins). Although the particulars of the process of the development of these obstructions are slightly different, it is hypothesized that obstructive complications occur mainly as a consequence of recurrent episodes of acute pancreatitis, which may ultimately result in fibrosis and scarring within and around the pancreatic gland[30,31]. An additional contributing factor to obstruction can be PPC, especially in the region of the pancreatic head[32]. Duodenal obstruction usually occurs in the second or third part of the duodenum[33]. It has been suggested that an underlying mechanism in its evolution is duodenal ischemia caused by arterial narrowing and thrombosis in the region of inflammatory mass in the pancreatic head[34]. An uncommon form of CP is groove pancreatitis or paraduodenal pancreatitis characterized by inflammation in the ‘groove’ between the duodenal wall and the pancreatic head[35]. The pathophysiology of this particular condition remains unclear, despite many suggested theories[36]. Among the various pathological findings of groove pancreatitis, fibroinflammatory process in the pancreatiduodenal groove has been described as the only consistent finding in this disease[37]. Groove pancreatitis is more common in middle-aged men and is strongly associated with history of alcohol consumption and tobacco smoking[38].

Prevalence and main clinical problems: Biliary strictures in patients with CP are relatively common with a prevalence of 3% to 23% and a mean of 6%[39]. Some patients with biliary obstruction may be asymptomatic and have only modestly deranged liver function tests[40]. However, common bile duct obstruction may lead to jaundice, persistent cholestasis, acute cholangitis, and secondary biliary cirrhosis[41]. Timely treatment of symptomatic strictures is required to prevent these secondary complications[40].

Duodenal obstruction is much rarer, with a prevalence of 0.5% to 13% and a mean of 1.2%[39]. Patients usually present with symptoms of gastric outlet obstruction such as vomiting, fluid and electrolyte imbalance, and weight loss.

The prevalence of major peripancreatic vein thrombosis varies from 10.9% to 22.0% with a pooled prevalence of 11.6%[42,43]. Splenic vein is mainly involved (up to 80.6%), followed by portal vein. Splenic vein thrombosis leads to left-side portal hypertension; these patients are at risk of development of gastric varices, splenomegaly, and severe variceal bleeding, which reportedly occurs in 4%-17% of all cases[44]. Several other splenic complications such as spontaneous splenic rupture, intrasplenic PPC, and splenic infraction have also been reported, but their prevalence remains well below 1%[45].

***Group III: Pancreatic hemorrhages***

Main pathophysiology: The third group of complications comprises all pancreatic hemorrhages due to the erosion of major intra and peripancreatic vessels, mainly arteries. Local inflammation, possibly combined with local release of pancreatic enzymes, pressure necrosis from ductal calcifications, and PPC may result in either pseudoaneurysm (PA) formation or bleeding into pre-existing PPC, which transforms PPC into PA[46,47].

Prevalence and main clinical problems: Although pancreatic bleeding in patients with CP is considered uncommon, the prevalence among in-patient cohorts is reportedly 4.6% to 7.7%[48,49]. Splenic artery is the most commonly involved vessel, followed by gastroduodenal and pancreaticoduodenal arteries[31,50]. As severity of blood loss and patients’ hemodynamical status depend on the rupture of PA, it is important from the clinical point of view distinguish between non-ruptured (contains PA) and ruptured PA. Patients with non-ruptured PA have the best prognosis, as blood loss is relatively small and the effect of self-tamponade can provide spontaneous hemostasis[51]. Usually, these patients present with abdominal pain combined with symptoms of moderate blood loss, or sometimes even without the latter. Radiological imaging is essential to establish the diagnosis. Diagnosis of PA is usually made on the basis of abdominal contrast-enhanced CT (CECT) scan done for evaluation of the etiology of abdominal pain[42].

Almost two-thirds of patients with PA have ruptured PA that is associated with much more severe hemorrhage and often with shock[48]. The most common site of rupture is the gastrointestinal tract (GIT), presenting as acute upper GIT bleeding with hematemesis and/or melena[52]. Rarely, PA can rupture into the PD and further into GIT through the papilla of Vater, leading to *hemosuccus pancreaticus*[53]. In most cases, this condition is associated with diagnostic difficulties because of the concealed source of bleeding. Correct diagnosis is commonly made only after many episodes of bleedings and numerous endoscopic evaluations and CECT scans. High index of suspicion should arise if the triad of symptoms *i.e.* GIT bleeding, abdominal pain and hyperamylasemia, is present[47]. The two other possible sites of PA rupture are the abdominal cavity, presenting as massive intrabdominal hemorrhage, and the retroperitoneum, presenting as retroperitoneal hematoma[54,55]. Acute GIT hemorrhages in patients with CP, which are not directly associated with CP (*e.g.,* variceal bleeding, peptic ulcer bleeding, Mallory-Weiss syndrome), are not included in this group of complications.

***Group IV: Pancreatic insufficiency***

Main pathophysiology: The fourth group represents complications due to extensive loss of the functioning pancreatic parenchyma, leading to pancreatic exocrine and endocrine insufficiency.

Prevalence and main clinical problems:As damage to the pancreatic tissue is a continuous process throughout the course of the disease, the prevalence of pancreatic exocrine insufficiency (PEI) in patients with CP increases steadily with times, being from 20% in early CP to 94% in the late phase of the disease[56,57]. Long duration of CP (> 30 years) is associated with > 80% prevalence of PEI[58]. Patients’ main complaints are steatorrhea, weight loss, flatulence, and abdominal discomfort. If untreated, the deficit of fat-soluble vitamins may lead to secondary complications (osteoporosis, fractures, immunodeficiency, and infections)[59].

Diabetes mellitus (DM) secondary to pancreatic diseases or pancreatic surgery is classified as pancreatogenic diabetes or type 3c DM (T3cDM) according to the current classification of DM[60]. The prevalence of DM in CP is between 25% and 80%[61,62]. Similar to PEI, T3cDM shows a clear correlation with duration of CP. In CP patients with associated T3cDM, blood glucose control may be complicated due to the loss of glucagon response to hypoglycemia, food malabsorption, and irregular eating patterns because of debilitating pain and/or continuous alcohol abuse[63].

The proposed classification does not include infectious complications of CP. The authors of the classification believe that infectious complications are mainly caused by exacerbations of pancreatitis: ‘Acute’ or ‘acute on chronic’ pancreatitis. Secondary complications are also excluded. Although it is well known that all complications of CP can lead to secondary complications (*e.g.,* biliary obstruction, to cholangitis or biliary cirrhosis; duodenal obstruction, to fluid and electrolytes imbalance; portal hypertension, to bleeding from esophageal varices; PEI, to osteopathy; diabetes, to possible decompensation of *etc*), they remain beyond the scope of this classification.

**RESULTS**

***Patients and surgical treatment***

All surgically treated CP patients, operated on at a single referral hospital between 1997 and 2021, were prospectively enrolled. A total of 166 patients were subjected to surgical management due to chronic pain or local complications of CP. The average rate of surgical treatment of CP was 18.1% from all patients admitted due to CP. The mean age of the patients was 49.8 ± 9.9 years; there were 140 males (84.3%) and 26 females (Table 1). In 148 patients (89.2%), CP was alcohol-induced; in the remaining cases, the etiology was idiopathic or rare causes. The median duration of symptomatic CP before surgical treatment was 18 mo.

Similar to a previous study[64], the most common indication for surgical treatment was chronic abdominal pain, being the predominant indication in 112 cases (67.5%). Local complications of CP were the predominant indication for surgical treatment in 54 cases (32.5%). However, almost half of the patients (81 patients, 48.8%) had had at least one local complication of CP before surgical treatment. The clinical relevance of these was highly variable (from asymptomatic PPC to ruptured PA). Ten patients (6.0%) had more than one local complication. Besides local anatomical complications, 52 patients (31.3%) had PEI and 45 patients (27.1%) had T3cDM prior to surgical treatment. Surgical treatment was pancreatic resection in 60 cases (36.2%), pancreatic drainage operation in 93 cases (56.0%), and extrapancreatic palliative procedure in 13 cases (7.8%; Table 2). There was no perioperative mortality. Cumulative Kaplan-Meier 10-year survival and median survival were 70.4% and 13.9 years, respectively. Median follow-up was 7.2 years. During follow-up 12 patients required secondary surgery, mostly due to emerged new local complications of CP (predominantly biliary stenosis).

***Prevalence of complications of CP prior to, and following surgical treatment***

The impact of surgical treatment on the occurrence of the *de novo* complications of CP during postoperative years was assessed according to the above proposed pathophysiological classification of complications of CP (Figure 1). The prevalence of PD complications was at baseline (before surgical treatment of CP) 20.5% (Figure 3); 10.8% of the patients had PPC, and 9.6% had various types of PF (Table 3). Endoscopic PD stenting precedes to surgical therapy in two out of 16 patients (12.5%) with PF. Further surgical treatment was undertaken due to continuous PD leakage. Surgical treatment demonstrated high effectiveness in decompressing PD, with very low risk of new ‘PD complications’ during follow-up (only one new PPC developed).

Peripancreatic complications showed a baseline prevalence of 23.5% (39 patients); 3 patients had concurrent biliary tract and duodenal or venous obstruction. The most common complication was biliary tract obstruction with 29 cases (17.5%), 8 patients had duodenal obstruction (4.8%) and venous occlusion was seen in 5 patients (3.0%). Endoscopic common bile stenting precedes to surgical therapy in 18 of 29 cases (62.1%) of patients with common bile duct stenosis. Further surgical treatment was indicated because of unsuccessful endoscopic treatment (defined as inconsistent effect of endoscopic stenting. During follow-up 13 new complications were documented in 11 patients, which resulted in a 15-year Kaplan-Meier prevalence of 12.1% of new peripancreatic complications. The total 15-year prevalence of peripancreatic complications was 35.6%. The most common among them was biliary tract obstruction (8 patients), followed by venous thrombosis (4 patients) and duodenal obstruction in 1 case. Five patients with biliary stenosis were managed *via* endoscopic stenting, and the remaining 3 patients needed secondary surgery.

As the occurrence of new complications requiring retreatment is a major drawback, we re-evaluated the distribution of these complications by the surgical subgroups depending on the type of surgical procedure applied. Analysis was performed for three subgroups: Pancreatic drainage operations, pancreatic resections (excluding Whipple’s procedure), and Whipple’s pancreatoduodenal resection as the only procedure incorporating new biliary and gastric bypasses (Table 4).

The analysis revealed differences in the occurrence of new peripancreatic complications. No new complications appeared in the group of Whipple’s procedure (11 patients); among the other types of pancreatic resections (49 patients), five complications occurred and in the group of pancreatic drainage operations (93 patients), there were eight complications. The 15-year Kaplan-Meier prevalence of peripancreatic complications following surgical treatment of CP was 0%, 11.4%, and 16.5%, respectively (Figure 4A).

The baseline prevalence of pancreatic hemorrhages was 10.2% (17 patients). There were 10 cases (58.8%) of ruptured pancreatic PA and 7 cases of contained PA. Ruptured PA presented as an acute life-threatening intraabdominal hemorrhage in 2 cases and as an acute recurrent gastrointestinal hemorrhage in 8 cases: Fistulation into GIT occurred in 6 cases and into PD, in 2 cases (*hemosuccus pancreaticus*). All patients with ruptured PA were treated *via* pancreatic resection. All but 1 patient with contained PA underwent intra-aneurysmatic hemostasis and a pancreatic drainage procedure. In 1 case, the affected part of pancreas was resected. Surgical treatment of pancreatic hemorrhages was highly effective: There were no recurring hemorrhages among patients with PA, nor were there new hemorrhages among the entire surgically treated cohort, regardless of the indication for surgical treatment of CP.

Pancreatic insufficiency was evaluated for two subgroups: PEI and T3cDM. Prior to surgical treatment, 73 patients (44.0%) had one of these or both. The prevalence of PEI was 31.3% (52 patients) and the prevalence of T3cDM was 27.1% (45 patients). During follow-up, a steady and almost synchronous increase in both complications was evident, resulting in a 15-year Kaplan-Meier prevalence of 66.4% and 47.1%, respectively. The 15-year Kaplan-Meier prevalence of either exocrine or endocrine insufficiency was 74.5%.

Re-evaluation of the development of pancreatic insufficiency was performed for the surgical subgroups depending on the type of surgical procedure. The highest rate of new cases of PEI was seen in patients undergoing Whipple’s pancreatoduodenal resection (Figure 4B). According to Cox regression analysis, hazard ratio for the development of new cases of PEI was 9.3 [95% confidence interval (CI): 3.6-24.2] in the group of Whipple’s procedure and 1.9 (95%CI: 0.8-4.2) in the group of other resections, compared to pancreatic drainage operations. Development of endocrine insufficiency did not show any significant dependency on the type of surgery; however, the rate of T3cDM was slightly higher for patients undergoing distal pancreatectomy (Figure 4C).

**DISCUSSION**

This study proposed a new pathophysiological classification of complications of CP, reported their prevalence in a surgically treated cohort, and assessed the impact of surgical treatment on occurrence of new complications during the further course of the disease. As there is currently no treatment to reverse or delay disease progression in CP, clinical management consists primarily of screening for and treating of complications[3]. The most effective treatment of complications is pathophysiological treatment. The proposed classification allows the easy determination of the predominant pathophysiologic mechanism. This could be beneficial for clinical decision making, as it provides an opportunity for more comprehensive judgement on patient’s needs on the one hand, and on the pros and cons of the treatment under consideration, on the other. Moreover, this classification could be used as an instrument for quality improvement in the treatment of CP. We strongly believe that the potential of any treatment to avoid further complications of CP would serve, besides known indicators of quality of treatment (*e.g.,* pain relief, quality of life), as an additional relevant indicator.

The goal of the surgical treatment of CP is usually to decompress PD or to resect the nidus of chronic inflammation, and to eliminate local complications of CP. In our study, the clinical impact of surgical treatment on different complications of CP was highly variable and clearly dependent on the underlying predominant pathophysiological mechanism. The first group of complications (PD complications) were effectively treated by pancreatic drainage operations, as well as by pancreaticojejunostomies created during pancreatic resection. The achieved effect was long lasting over time: Only 1 PPC developed during follow-up *vs* 34 preoperative complications. Unfortunately, we failed to find previous data about the recurrence rate of PPC or PF after PD drainage for comparison. Less radical treatment modalities, *e.g.,* anastomoses with PPC and endoscopic drainage, have shown relatively high rate of recurrence. According to Ye *et al*[65], the recurrence rate of PPC was 11.2% after pseudocystojejunostomy and 7.5% after pseudocystogastrostomy, with an average follow-up of 42.7 mo[65]. However, the authors did not provide data about the etiology of the PPC (acute or chronic pancreatitis). Endoscopic treatment seems to be associated with a higher recurrence rate: Rückert *et al*[66] reported a recurrence rate of 23.3% after endoscopic drainage during 42.2 mo of follow-up and underlined the high recurrence risk of CP-associated PPC[66]. Farias *et al*[67] compared endoscopic and surgical drainage (mainly *via* pseudocystogastrostomy) of PPC in a meta-analysis and found no significant difference in their recurrence rates[67]. Our data support surgical decompression of PD in the case of CP-provoked PPC and PF. High effectiveness of surgical decompression is attributable to the most radical relief of main pathology (PD obstruction and intraductal hypertension).

The impact of surgical treatment on peripancreatic complications revealed significant dependency on the surgical method used. During follow-up, there were no new complications in the Whipple’s procedure group, which can be explained by the nature of this procedure (creation of new bilioenteric and gastroenteric anastomoses). After the other surgical procedures (pancreatic drainage operations and non-Whipple’s pancreatic resections, mostly Beger or Berne modifications of pancreatic head resection, and pancreatic tail resection, new peripancreatic complications developed, which necessitated readmissions and reoperations. In most cases, there were biliary strictures (8 patients) and venous thrombosis of SV or PV (4 patients); 1 patient developed duodenal obstruction. The causes of new peripancreatic complications in the postoperative period can be variable. It seems that among the predominant causes are further development of the fibrotic tissue and the process of scarring within and around the pancreas. This theory is indirectly supported by the results of endoscopic stenting of CP-associated biliary strictures. Several studies have found that long-lasting stenting (10-12 mo) is more effective than short-term therapy (3-6 mo), indicating persistent fibrosis and scarring[68,69]. The present study showed that biliary strictures can occur even many years after surgical treatment of CP. In these cases, exacerbations of CP, whether clinical or subclinical, might be responsible, as they are associated with additional extrinsic compression due to edema or development of PPC in the region of the pancreatic head[70]. The ability to avoid new peripancreatic complications is one of the obvious advantages of Whipple’s procedure in the treatment of CP, as reported earlier by Diener *et al*[71] in the ChroPac trial and by Müller *et al*[72]. Whether this advantage of the Whipple’s procedure is sufficient to prefer this operation to other surgical options remains a subject of discussion. In fact, Whipple’s operation also has disadvantages, such as longer operating time, and according to most studies, higher perioperative morbidity and mortality, and higher rate of postoperative PEI.

The third group of complications (pancreatic hemorrhage) is associated with the poorest prognosis. Even with prompt diagnosis and immediate therapy, the mortality rate reported in earlier studies is 15% to 50%[73]. In the past two decades, due to the enormous improvement in radiological techniques and instrumentation, angiographic treatment as the first-line therapy has been widely employed to stop bleeding from visceral PA in hemodynamically stable patients. In a recent meta-analysis Sagar *et al*[74] reported a technical success rate of 88%, a clinical success rate of 86%, a rebleeding rate of 16.3%, and a morality rate of 8% for endovascular therapy[74]. Surgical treatment is reserved for patients in whom vascular interventional therapy has failed or is not accessible, as well as in those with unstable vital signs; during the study period we had 17 such patients. Our surgical approach was relatively radical. In cases of recurrent GIT bleeding from the fistulation of PA and ineffective endovascular therapy, or in cases of ongoing bleeding in an unstable patient, surgical treatment always consisted in resection of the affected area of the pancreas.

In most such cases, pancreatic tail resection was performed (8 cases), as hemorrhages emerged from the splenic artery, but in 2 cases pancreatic head resection was necessary. In cases of contained PA, the treatment of choice was intra-aneurysmatic hemostasis followed by pancreatic drainage operation. This approach resulted in a highly effective treatment result; there were no recurrent pancreatic hemorrhages in our cohort during follow-up (median 7.2 years). As re-bleedings occurred after surgery in our cohort and we managed to achieve zero perioperative mortality, we are convinced that surgical therapy remains an important highly effective treatment modality for patients with pancreatic hemorrhage. In unstable patients, surgery should be the first-line therapy; in hemodynamically stable patients, surgery should be indicated in cases of unsuccessful endovascular therapy, as the next step of treatment.

Besides effective treatment of pancreatic hemorrhages, surgical therapy demonstrated the potential to avoid pancreatic hemorrhages; there were no episodes of pancreatic hemorrhage during follow-up in the entire surgically treated cohort. One explanation of this might be the beneficial effect of PD decompression: Previous studies have revealed PPC as the most important risk factor for development of PA and pancreatic hemorrhage[42]. Regarding occurrence of chronic PPC, which usually precedes PD obstruction and intraductal hypertension[75], surgical PD decompression has a preventive effect on development of PPC, as well as on its transformation into PA.

The fourth group of complications (pancreatic insufficiency) showed continuous steady deterioration of pancreatic function. A similar result, *i.e.* impairment of pancreatic function over time, has been repeatedly demonstrated earlier, most recently by Kempeneers *et al*[76], on the basis of data from the Dutch Chronic Pancreatitis Registry[76]. Comparison of the surgical options revealed higher rate of PEI after Whipple’s pancreatoduodenal resection (compared to the other types of surgery) and slightly higher rate of T3cDM in the group of pancreatic tail resection.

Several studies have found that early surgery could be beneficial in terms of slowing impairment of pancreatic function[77,78]. The data of the present study are insufficient to provide any additional information regarding this effect, as our patients were clearly not ‘early cases’ of CP. An important contribution to the understanding of complications of CP was made by a study of Olesen *et al*[79]’s. The cluster analysis used by these authors distinguished between inflammatory, fibrotic and functional complications and they assessed association between clusters and etiological risks. The present pathophysiological classification is aimed at facilitating clinical decision-making: *e.g.,* should one eliminate PD problems *vs* peripancreatic problems *vs* pancreatic hemorrhage *vs* treat pancreatic insufficiency?

Based on pathophysiological grouping, our analysis shows that there exist no ideal surgical options suitable for all cases of CP. Nevertheless, despite the lack of evidence supporting the universal superiority of any available surgical procedure, it is obvious that each of them has its own specific advantages. Thus, the choice of the surgical procedure should proceed from at least four aspects; predominant indication for surgery; anatomical changes of the pancreatic gland; presence and entity of local complications of CP; and procedure-specific risks of surgery (immediate and long-term). This is consistent with the conclusion by Frola *et al*[80] according to which a tailored approach to CP patients is mandatory[80].

***Limitations***

Our center is a tertiary care referral center and hence the prevalence of complications of CP may be an overestimation.

**CONCLUSION**

The proposed complication classification improves the understanding of CP. It could be beneficial for clinical decision making, as it provides an opportunity for more comprehensive judgement on patient’s needs on the one hand, and on the pros and cons of the treatment under consideration, on the other. Existing complications of CP and the risk for development of new complications should be among the main determinants of surgical choice.

**ARTICLE HIGHLIGHTS**

***Research background***

Chronic pancreatitis (CP) is a long-lasting disease frequently associated with complications for which there exists so far no comprehensive pathophysiological classification.

***Research motivation***

The motivation of present study was: To propose a pathophysiological classification of the complications of CP; evaluate their prevalence in a surgical cohort prior to, and following surgical management; and assess the impact of the surgical treatment on the occurrence of new complications of CP during follow-up.

***Research objectives***

To describe the full diversity of severe complications of CP seen in our cohort during 20 years of study using proposed classification of complications of CP; and to assess the impact of surgical treatment on the development of new complications during follow-up.

***Research methods***

After institutional review board approval, a prospective observational cohort study with long-term follow-up (up to 20.4 years) was conducted. All consecutive single-center adult patients (≥ 18 years of age) with CP according to the criteria of the American Pancreas Association subjected to surgical management between 1997 and 2021, were included. The prevalence of the complications of CP was evaluated, according to the proposed classification, in a surgical cohort of 166 patients.

***Research results***

We distinguished four groups of complications: Pancreatic duct complications, peripancreatic complications, pancreatic hemorrhages, and pancreatic insufficiency (exocrine and endocrine). Their baseline prevalence was 20.5%, 23.5%, 10.2%, 31.3% and 27.1%, respectively. Surgical treatment was highly effective in avoiding new complications in the first and third groups. In the group of peripancreatic complications, the 15-year Kaplan-Meier prevalence of new complications was 12.1%. The prevalence of pancreatic exocrine and endocrine insufficiency increased during follow-up, being 66.4% and 47.1%, respectively, 15 years following surgery.

***Research conclusions***

The proposed complication classification improves the understanding of CP. It could be beneficial for clinical decision making, as it provides an opportunity for more comprehensive judgement on patient’s needs on the one hand, and on the pros and cons of the treatment under consideration, on the other. The presence of the complications of CP and the risk of development of new ones should be among main determinants of surgical choice.

***Research perspectives***

It would be interesting to compare the effectiveness of the surgical and endoscopic treatment of complications of CP using our proposed classification.

**REFERENCES**

1 **Klöppel G**, Maillet B. Pseudocysts in chronic pancreatitis: a morphological analysis of 57 resection specimens and 9 autopsy pancreata. *Pancreas* 1991; **6**: 266-274 [PMID: 1862065]

2 **Ammann RW**. Diagnosis and management of chronic pancreatitis: current knowledge. *Swiss Med Wkly* 2006; **136**: 166-174 [PMID: 16633964]

3 **Ramsey ML**, Conwell DL, Hart PA. Complications of Chronic Pancreatitis. *Dig Dis Sci* 2017; **62**: 1745-1750 [PMID: 28281169 DOI: 10.1007/s10620-017-4518-x]

4 **Majumder S**, Chari ST. Chronic pancreatitis. *Lancet* 2016; **387**: 1957-1966 [PMID: 26948434 DOI: 10.1016/S0140-6736(16)00097-0]

5 **Murruste M**, Kirsimägi Ü, Kase K, Saar S, Talving P. Long-term survival, risk factors and causes of mortality in surgically treated chronic pancreatitis. *Pancreatology* 2021; **21**: 714-723 [PMID: 33727036 DOI: 10.1016/j.pan.2021.03.003]

6 **Jawad ZAR**, Kyriakides C, Pai M, Wadsworth C, Westaby D, Vlavianos P, Jiao LR. Surgery remains the best option for the management of pain in patients with chronic pancreatitis: A systematic review and meta-analysis. *Asian J Surg* 2017; **40**: 179-185 [PMID: 26778832 DOI: 10.1016/j.asjsur.2015.09.005]

7 **Kleeff J**, Stöß C, Mayerle J, Stecher L, Maak M, Simon P, Nitsche U, Friess H. Evidence-Based Surgical Treatments for Chronic Pancreatitis. *Dtsch Arztebl Int* 2016; **113**: 489-496 [PMID: 27545699 DOI: 10.3238/arztebl.2016.0489]

8 **Büchler MW**, Martignoni ME, Friess H, Malfertheiner P. A proposal for a new clinical classification of chronic pancreatitis. *BMC Gastroenterol* 2009; **9**: 93 [PMID: 20003450 DOI: 10.1186/1471-230X-9-93]

9 **Conwell DL**, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortele KJ, Levy MJ, Kwon R, Lieb JG, Stevens T, Toskes PP, Gardner TB, Gelrud A, Wu BU, Forsmark CE, Vege SS. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. *Pancreas* 2014; **43**: 1143-1162 [PMID: 25333398 DOI: 10.1097/MPA.0000000000000237]

10 **Klöppel G**. Chronic pancreatitis, pseudotumors and other tumor-like lesions. *Mod Pathol* 2007; **20 Suppl 1**: S113-S131 [PMID: 17486047 DOI: 10.1038/modpathol.3800690]

11 **Kleeff J**, Whitcomb DC, Shimosegawa T, Esposito I, Lerch MM, Gress T, Mayerle J, Drewes AM, Rebours V, Akisik F, Muñoz JED, Neoptolemos JP. Chronic pancreatitis. *Nat Rev Dis Primers* 2017; **3**: 17060 [PMID: 28880010 DOI: 10.1038/nrdp.2017.60]

12 **Campisi A**, Brancatelli G, Vullierme MP, Levy P, Ruszniewski P, Vilgrain V. Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis. *Clin Radiol* 2009; **64**: 903-911 [PMID: 19664481 DOI: 10.1016/j.crad.2009.05.005]

13 **Negi S**, Singh A, Chaudhary A. Pain relief after Frey's procedure for chronic pancreatitis. *Br J Surg* 2010; **97**: 1087-1095 [PMID: 20632276 DOI: 10.1002/bjs.7042]

14 **Parakh A**, Tirkes T. Advanced imaging techniques for chronic pancreatitis. *Abdom Radiol (NY)* 2020; **45**: 1420-1438 [PMID: 31428813 DOI: 10.1007/s00261-019-02191-0]

15 **Howell DA**, Elton E, Parsons WG. Endoscopic management of pseudocysts of the pancreas. *Gastrointest Endosc Clin N Am* 1998; **8**: 143-162 [PMID: 9405756]

16 **Banks PA**, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013; **62**: 102-111 [PMID: 23100216 DOI: 10.1136/gutjnl-2012-302779]

17 **Tringali A**, Boskoski I, Costamagna G. The role of endoscopy in the therapy of chronic pancreatitis. *Best Pract Res Clin Gastroenterol* 2008; **22**: 145-165 [PMID: 18206819 DOI: 10.1016/j.bpg.2007.10.021]

18 **Sachs M**, Falley J, Schachtel U. [Pancreatogenic pleuritis and pancreatico-pleural fistula: pathogenesis, diagnosis and therapy]. *Zentralbl Chir* 1991; **116**: 809-818 [PMID: 1950216]

19 **Dumonceau JM**, Delhaye M, Tringali A, Arvanitakis M, Sanchez-Yague A, Vaysse T, Aithal GP, Anderloni A, Bruno M, Cantú P, Devière J, Domínguez-Muñoz JE, Lekkerkerker S, Poley JW, Ramchandani M, Reddy N, van Hooft JE. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Updated August 2018. *Endoscopy* 2019; **51**: 179-193 [PMID: 30654394 DOI: 10.1055/a-0822-0832]

20 **Klöppel G**. Pseudocysts and other non-neoplastic cysts of the pancreas. *Semin Diagn Pathol* 2000; **17**: 7-15 [PMID: 10721803]

21 **Zerem E**, Hauser G, Loga-Zec S, Kunosić S, Jovanović P, Crnkić D. Minimally invasive treatment of pancreatic pseudocysts. *World J Gastroenterol* 2015; **21**: 6850-6860 [PMID: 26078561 DOI: 10.3748/wjg.v21.i22.6850]

22 **Gouyon B**, Lévy P, Ruszniewski P, Zins M, Hammel P, Vilgrain V, Sauvanet A, Belghiti J, Bernades P. Predictive factors in the outcome of pseudocysts complicating alcoholic chronic pancreatitis. *Gut* 1997; **41**: 821-825 [PMID: 9462217 DOI: 10.1136/gut.41.6.821]

23 **Gumaste VV**, Pitchumoni CS. Pancreatic pseudocyst. *Gastroenterologist* 1996; **4**: 33-43 [PMID: 8689144]

24 **da Cunha JE**, Machado M, Bacchella T, Penteado S, Mott CB, Jukemura J, Pinotti HW. Surgical treatment of pancreatic ascites and pancreatic pleural effusions. *Hepatogastroenterology* 1995; **42**: 748-751 [PMID: 8751245]

25 **Kaman L**, Behera A, Singh R, Katariya RN. Internal pancreatic fistulas with pancreatic ascites and pancreatic pleural effusions: recognition and management. *ANZ J Surg* 2001; **71**: 221-225 [PMID: 11355730 DOI: 10.1046/j.1440-1622.2001.02077.x]

26 **Thomas CT**, Hinton PJ, Thomas E. Spontaneous pancreatic duct-colon fistula. *J Clin Gastroenterol* 1986; **8**: 69-73 [PMID: 3517133 DOI: 10.1097/00004836-198602000-00015]

27 **Bintcliffe OJ**, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. *Eur Respir Rev* 2016; **25**: 303-316 [PMID: 27581830 DOI: 10.1183/16000617.0026-2016]

28 **Clark K,** Gross KE. Pancreatico-Pleural Fistula and Pancreatico-Pericardial Fistula: Unusual Complications of Pancreatitis. *Am J Respiratory Critical Care Med* 2019; **199:** A6439

29 **Raza SS**, Hakeem A, Sheridan M, Ahmad N. Spontaneous pancreatic pseudocyst-portal vein fistula: a rare and potentially life-threatening complication of pancreatitis. *Ann R Coll Surg Engl* 2013; **95**: e7-e9 [PMID: 23317711 DOI: 10.1308/003588413x13511609955616]

30 **Sarles H**, Sahel J. Cholestasis and lesions of the biliary tract in chronic pancreatitis. *Gut* 1978; **19**: 851-857 [PMID: 361513 DOI: 10.1136/gut.19.9.851]

31 **Mallick IH**, Winslet MC. Vascular complications of pancreatitis. *JOP* 2004; **5**: 328-337 [PMID: 15365199]

32 **Bernades P**, Baetz A, Lévy P, Belghiti J, Menu Y, Fékété F. Splenic and portal venous obstruction in chronic pancreatitis. A prospective longitudinal study of a medical-surgical series of 266 patients. *Dig Dis Sci* 1992; **37**: 340-346 [PMID: 1735356 DOI: 10.1007/BF01307725]

33 **Bradley EL 3rd**, Clements JL Jr. Idiopathic duodenal obstruction: an unappreciated complication of pancreatitis. *Ann Surg* 1981; **193**: 638-648 [PMID: 7235767 DOI: 10.1097/00000658-198105000-00015]

34 **Satake K**, Umeyama K. "Idiopathic" duodenal obstruction due to chronic pancreatitis. *Am Surg* 1984; **50**: 534-537 [PMID: 6486569]

35 **Latham J**, Sanjay P, Watt DG, Walsh SV, Tait IS. Groove pancreatitis: a case series and review of the literature. *Scott Med J* 2013; **58**: e28-e31 [PMID: 23596036 DOI: 10.1177/0036933012474610]

36 **Shin LK**, Jeffrey RB, Pai RK, Raman SP, Fishman EK, Olcott EW. Multidetector CT imaging of the pancreatic groove: differentiating carcinomas from paraduodenal pancreatitis. *Clin Imaging* 2016; **40**: 1246-1252 [PMID: 27636383 DOI: 10.1016/j.clinimag.2016.08.004]

37 **Patel BN**, Brooke Jeffrey R, Olcott EW, Zaheer A. Groove pancreatitis: a clinical and imaging overview. *Abdom Radiol (NY)* 2020; **45**: 1439-1446 [PMID: 31559471 DOI: 10.1007/s00261-019-02239-1]

38 **Arvanitakis M**, Rigaux J, Toussaint E, Eisendrath P, Bali MA, Matos C, Demetter P, Loi P, Closset J, Deviere J, Delhaye M. Endotherapy for paraduodenal pancreatitis: a large retrospective case series. *Endoscopy* 2014; **46**: 580-587 [PMID: 24839187 DOI: 10.1055/s-0034-1365719]

39 **Vijungco JD**, Prinz RA. Management of biliary and duodenal complications of chronic pancreatitis. *World J Surg* 2003; **27**: 1258-1270 [PMID: 14534824 DOI: 10.1007/s00268-003-7246-7]

40 **Abdallah AA**, Krige JE, Bornman PC. Biliary tract obstruction in chronic pancreatitis. *HPB (Oxford)* 2007; **9**: 421-428 [PMID: 18345288 DOI: 10.1080/13651820701774883]

41 **Costamagna G**, Boškoski I. Current treatment of benign biliary strictures. *Ann Gastroenterol* 2013; **26**: 37-40 [PMID: 24714594]

42 **Gorsi U**, Agarwal V, Nair V, Kang M, Kalra N, Sreedhara BC, Gupta R, Rana SS, Dutta U, Sandhu MS. Endovascular and percutaneous transabdominal embolisation of pseudoaneurysms in pancreatitis: an experience from a tertiary-care referral centre. *Clin Radiol* 2021; **76**: 314.e17-314.e23 [PMID: 33526255 DOI: 10.1016/j.crad.2020.12.016]

43 **Gabrielli D**, Taglialatela F, Mantini C, Giammarino A, Modestino F, Cotroneo AR. Endovascular Treatment of Visceral Artery Pseudoaneurysms in Patients with Chronic Pancreatitis: Our Single-Center Experience. *Ann Vasc Surg* 2017; **45**: 112-116 [PMID: 28602898 DOI: 10.1016/j.avsg.2017.05.035]

44 **Ru N**, He CH, Ren XL, Chen JY, Yu FF, Yan ZJ, Guo JY, Zhu JH, Wang YC, Qian YY, Pan J, Hu LH, Li ZS, Zou WB, Liao Z. Risk factors for sinistral portal hypertension and related variceal bleeding in patients with chronic pancreatitis. *J Dig Dis* 2020; **21**: 468-474 [PMID: 32584511 DOI: 10.1111/1751-2980.12916]

45 **Jain D**, Lee B, Rajala M. Atraumatic Splenic Hemorrhage as a Rare Complication of Pancreatitis: Case Report and Literature Review. *Clin Endosc* 2020; **53**: 311-320 [PMID: 31337192 DOI: 10.5946/ce.2019.087]

46 **Eckhauser FE**, Stanley JC, Zelenock GB, Borlaza GS, Freier DT, Lindenauer SM. Gastroduodenal and pancreaticoduodenal artery aneurysms: a complication of pancreatitis causing spontaneous gastrointestinal hemorrhage. *Surgery* 1980; **88**: 335-344 [PMID: 6968101]

47 **Sakorafas GH**, Sarr MG, Farley DR, Que FG, Andrews JC, Farnell MB. Hemosuccus pancreaticus complicating chronic pancreatitis: an obscure cause of upper gastrointestinal bleeding. *Langenbecks Arch Surg* 2000; **385**: 124-128 [PMID: 10796050 DOI: 10.1007/s004230050254]

48 **Bergert H**, Dobrowolski F, Caffier S, Bloomenthal A, Hinterseher I, Saeger HD. Prevalence and treatment of bleeding complications in chronic pancreatitis. *Langenbecks Arch Surg* 2004; **389**: 504-510 [PMID: 15173947 DOI: 10.1007/s00423-004-0478-7]

49 **Nagarajan K**, Sunilkumar D, Ramakrishnaiah VPN, Amuthabarathi M. Left Gastric Pseudoaneurysm in a Case of Chronic Pancreatitis: A Case Report With Review of Literature. *Vasc Endovascular Surg* 2021; **55**: 73-76 [PMID: 32869730 DOI: 10.1177/1538574420954309]

50 **Kalva SP**, Yeddula K, Wicky S, Fernandez del Castillo C, Warshaw AL. Angiographic intervention in patients with a suspected visceral artery pseudoaneurysm complicating pancreatitis and pancreatic surgery. *Arch Surg* 2011; **146**: 647-652 [PMID: 21339414 DOI: 10.1001/archsurg.2011.11]

51 **Vanlangenhove P**, Defreyne L, Kunnen M. Spontaneous thrombosis of a pseudoaneurysm complicating pancreatitis. *Abdom Imaging* 1999; **24**: 491-493 [PMID: 10475934 DOI: 10.1007/s002619900546]

52 **Balachandra S**, Siriwardena AK. Systematic appraisal of the management of the major vascular complications of pancreatitis. *Am J Surg* 2005; **190**: 489-495 [PMID: 16105542 DOI: 10.1016/j.amjsurg.2005.03.009]

53 **Sandblom P**. Gastrointestinal hemorrhage through the pancreatic duct. *Ann Surg* 1970; **171**: 61-66 [PMID: 5308032 DOI: 10.1097/00000658-197001000-00009]

54 **Yamakado K**, Nakatsuka A, Tanaka N, Takano K, Matsumura K, Takeda K. Transcatheter arterial embolization of ruptured pseudoaneurysms with coils and n-butyl cyanoacrylate. *J Vasc Interv Radiol* 2000; **11**: 66-72 [PMID: 10693716 DOI: 10.1016/s1051-0443(07)61284-6]

55 **Hsu JT**, Yeh CN, Hung CF, Chen HM, Hwang TL, Jan YY, Chen MF. Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. *BMC Gastroenterol* 2006; **6**: 3 [PMID: 16405731 DOI: 10.1186/1471-230X-6-3]

56 **Dumasy V**, Delhaye M, Cotton F, Deviere J. Fat malabsorption screening in chronic pancreatitis. *Am J Gastroenterol* 2004; **99**: 1350-1354 [PMID: 15233677 DOI: 10.1111/j.1572-0241.2004.30661.x]

57 **Li BR**, Pan J, Du TT, Liao Z, Ye B, Zou WB, Chen H, Ji JT, Zheng ZH, Wang D, Lin JH, Ning SB, Hu LH, Li ZS. Risk Factors for Steatorrhea in Chronic Pancreatitis: A Cohort of 2,153 Patients. *Sci Rep* 2016; **6**: 21381 [PMID: 26877248 DOI: 10.1038/srep21381]

58 **Nikfarjam M**, Wilson JS, Smith RC; Australasian Pancreatic Club Pancreatic Enzyme Replacement Therapy Guidelines Working Group. Diagnosis and management of pancreatic exocrine insufficiency. *Med J Aust* 2017; **207**: 161-165 [PMID: 28814218 DOI: 10.5694/mja16.00851]

59 **Duggan SN**, Smyth ND, O'Sullivan M, Feehan S, Ridgway PF, Conlon KC. The prevalence of malnutrition and fat-soluble vitamin deficiencies in chronic pancreatitis. *Nutr Clin Pract* 2014; **29**: 348-354 [PMID: 24727205 DOI: 10.1177/0884533614528361]

60 **Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.**. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003; **26 Suppl 1**: S5-20 [PMID: 12502614 DOI: 10.2337/diacare.26.2007.s5]

61 **Hart PA**, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, Goodarzi MO, Habtezion A, Korc M, Kudva YC, Pandol SJ, Yadav D, Chari ST; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer(CPDPC). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. *Lancet Gastroenterol Hepatol* 2016; **1**: 226-237 [PMID: 28404095 DOI: 10.1016/S2468-1253(16)30106-6]

62 **Olesen SS**, Poulsen JL, Novovic S, Nøjgaard C, Kalaitzakis E, Jensen NM, Engjom T, Tjora E, Waage A, Hauge T, Haas SL, Vujasinovic M, Barauskas G, Pukitis A, Ozola-Zālīte I, Okhlobystin A, Parhiala M, Laukkarinen J, Drewes AM. Multiple risk factors for diabetes mellitus in patients with chronic pancreatitis: A multicentre study of 1117 cases. *United European Gastroenterol J* 2020; **8**: 453-461 [PMID: 32213024 DOI: 10.1177/2050640620901973]

63 **Larsen S**. Diabetes mellitus secondary to chronic pancreatitis. *Dan Med Bull* 1993; **40**: 153-162 [PMID: 8495594]

64 **Tian X**, Ma Y, Gao H, Zhuang Y, Yang Y. Surgical options for control of abdominal pain in chronic pancreatitis patients. *J Pain Res* 2019; **12**: 2331-2336 [PMID: 31440077 DOI: 10.2147/JPR.S208212]

65 **Ye J**, Wang L, Lu S, Yang D, Hu W, Lu H, Zhang Y. Clinical study on cystogastrostomy and Roux-en-Y-type cystojejunostomy in the treatment of pancreatic pseudocyst: A single-center experience. *Medicine (Baltimore)* 2021; **100**: e25029 [PMID: 33725885 DOI: 10.1097/MD.0000000000025029]

66 **Rückert F**, Lietzmann A, Wilhelm TJ, Sold M, Kähler G, Schneider A. Long-term results after endoscopic drainage of pancreatic pseudocysts: A single-center experience. *Pancreatology* 2017; **17**: 555-560 [PMID: 28606430 DOI: 10.1016/j.pan.2017.06.002]

67 **Farias GFA**, Bernardo WM, De Moura DTH, Guedes HG, Brunaldi VO, Visconti TAC, Gonçalves CVT, Sakai CM, Matuguma SE, Santos MELD, Sakai P, De Moura EGH. Endoscopic versus surgical treatment for pancreatic pseudocysts: Systematic review and meta-analysis. *Medicine (Baltimore)* 2019; **98**: e14255 [PMID: 30813129 DOI: 10.1097/MD.0000000000014255]

68 **Lakhtakia S**, Reddy N, Dolak W, Ponchon T, Bruno MJ, Bourke MJ, Neuhaus H, Roy A, González-Huix Lladó F, Kortan PP, Peetermans J, Rousseau M, Costamagna G, Devière J; Benign Biliary Stenoses Working Group. Long-term outcomes after temporary placement of a self-expanding fully covered metal stent for benign biliary strictures secondary to chronic pancreatitis. *Gastrointest Endosc* 2020; **91**: 361-369.e3 [PMID: 31494135 DOI: 10.1016/j.gie.2019.08.037]

69 **Ramchandani M**, Lakhtakia S, Costamagna G, Tringali A, Püspöek A, Tribl B, Dolak W, Devière J, Arvanitakis M, van der Merwe S, Laleman W, Ponchon T, Lepilliez V, Gabbrielli A, Bernardoni L, Bruno MJ, Poley JW, Arnelo U, Lau J, Roy A, Bourke M, Kaffes A, Neuhaus H, Peetermans J, Rousseau M, Reddy DN. Fully Covered Self-Expanding Metal Stent vs Multiple Plastic Stents to Treat Benign Biliary Strictures Secondary to Chronic Pancreatitis: A Multicenter Randomized Trial. *Gastroenterology* 2021; **161**: 185-195 [PMID: 33741314 DOI: 10.1053/j.gastro.2021.03.015]

70 **Adler JM**, Gardner TB. Endoscopic Therapies for Chronic Pancreatitis. *Dig Dis Sci* 2017; **62**: 1729-1737 [PMID: 28258377 DOI: 10.1007/s10620-017-4502-5]

71 **Diener MK**, Hüttner FJ, Kieser M, Knebel P, Dörr-Harim C, Distler M, Grützmann R, Wittel UA, Schirren R, Hau HM, Kleespies A, Heidecke CD, Tomazic A, Halloran CM, Wilhelm TJ, Bahra M, Beckurts T, Börner T, Glanemann M, Steger U, Treitschke F, Staib L, Thelen K, Bruckner T, Mihaljevic AL, Werner J, Ulrich A, Hackert T, Büchler MW; ChroPac Trial Group. Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial. *Lancet* 2017; **390**: 1027-1037 [PMID: 28901935 DOI: 10.1016/S0140-6736(17)31960-8]

72 **Müller MW**, Friess H, Martin DJ, Hinz U, Dahmen R, Büchler MW. Long-term follow-up of a randomized clinical trial comparing Beger with pylorus-preserving Whipple procedure for chronic pancreatitis. *Br J Surg* 2008; **95**: 350-356 [PMID: 17933005 DOI: 10.1002/bjs.5960]

73 **Chiang KC**, Chen TH, Hsu JT. Management of chronic pancreatitis complicated with a bleeding pseudoaneurysm. *World J Gastroenterol* 2014; **20**: 16132-16137 [PMID: 25473165 DOI: 10.3748/wjg.v20.i43.16132]

74 **Sagar S**, Soundarajan R, Gupta P, Praveen Kumar M, Samanta J, Sharma V, Kochhar R. Efficacy of endovascular embolization of arterial pseudoaneurysms in pancreatitis: A systematic review and meta-analysis. *Pancreatology* 2021; **21**: 46-58 [PMID: 33303372 DOI: 10.1016/j.pan.2020.11.017]

75 **Andrén-Sandberg A**, Dervenis C. Pancreatic pseudocysts in the 21st century. Part I: classification, pathophysiology, anatomic considerations and treatment. *JOP* 2004; **5**: 8-24 [PMID: 14730118]

76 **Kempeneers MA**, Ahmed Ali U, Issa Y, van Goor H, Drenth JPH, van Dullemen HM, van Hooft JE, Poen AC, van Veldhuisen SL, Besselink MG, van Santvoort HC, Bruno MJ, Boermeester MA; Dutch Pancreatitis Study Group. Natural Course and Treatment of Pancreatic Exocrine Insufficiency in a Nationwide Cohort of Chronic Pancreatitis. *Pancreas* 2020; **49**: 242-248 [PMID: 32011528 DOI: 10.1097/MPA.0000000000001473]

77 **Yang CJ**, Bliss LA, Schapira EF, Freedman SD, Ng SC, Windsor JA, Tseng JF. Systematic review of early surgery for chronic pancreatitis: impact on pain, pancreatic function, and re-intervention. *J Gastrointest Surg* 2014; **18**: 1863-1869 [PMID: 24944153 DOI: 10.1007/s11605-014-2571-8]

78 **Issa Y**, Kempeneers MA, Bruno MJ, Fockens P, Poley JW, Ahmed Ali U, Bollen TL, Busch OR, Dejong CH, van Duijvendijk P, van Dullemen HM, van Eijck CH, van Goor H, Hadithi M, Haveman JW, Keulemans Y, Nieuwenhuijs VB, Poen AC, Rauws EA, Tan AC, Thijs W, Timmer R, Witteman BJ, Besselink MG, van Hooft JE, van Santvoort HC, Dijkgraaf MG, Boermeester MA; Dutch Pancreatitis Study Group. Effect of Early Surgery vs Endoscopy-First Approach on Pain in Patients With Chronic Pancreatitis: The ESCAPE Randomized Clinical Trial. *JAMA* 2020; **323**: 237-247 [PMID: 31961419 DOI: 10.1001/jama.2019.20967]

79 **Olesen SS**, Nøjgaard C, Poulsen JL, Haas SL, Vujasinovic M, Löhr M, Lindkvist B, Bexander L, Gulbinas A, Kalaitzakis E, Ebrahim M, Erchinger F, Engjom T, Roug S, Novovic S, Hauge T, Waage A, Laukkarinen J, Parhiala M, Pukitis A, Ozola-Zālīte I, Drewes AM; Scandinavian Baltic Pancreatic Club. Chronic Pancreatitis Is Characterized by Distinct Complication Clusters That Associate With Etiological Risk Factors. *Am J Gastroenterol* 2019; **114**: 656-664 [PMID: 30741740 DOI: 10.14309/ajg.0000000000000147]

80 **Frola C,** Somasundaram M, Hariharan D, Kolaityte V, Mohandas S, Stättner S, Yip VS. The role of Surgery in chronic pancreatitis. *Eur Surg* 2019; **51:** 114-120 [DOI: 10.1007/s10353-019-0591-z]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the University of Tartu (UT REC) Institutional Review Board, No. 291/T-1.

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 4, 2022

**First decision:** March 12, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Estonia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Kitamura K, Japan; Kumar A, India; Tan CL, China **A-Editor:** Liu X, China **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 Pathophysiological classification of complications of chronic pancreatitis.** 1References to the rates of prevalence. PEI: Pancreatic exocrine insufficiency; T3cDM: Type 3c diabetes mellitus.



**Figure 2 Main complications of chronic pancreatitis.** (1) Pancreatic duct complications: 1-A: Pancreatic pseudocyst; 1-B: Pancreatic ascites; 1-C: Pancreatic pleural effusion; (2) Peripancreatic complications: 2-A: Common bile duct stenosis; 2-B: Duodenal stenosis; 2-C: Venous thrombosis (splenic vein); 2-D: Left-side portal hypertension due to splenic vein thrombosis; (3) Pancreatic hemorrhages: 3-A: Peripancreatic pseudoaneurysm; 3-B: Ruptured pseudoaneurysm (into pancreatic duct–*hemosuccus pancreaticus*); and (4) Pancreatic exocrine and endocrine insufficiency due to extensive loss of functional pancreatic parenchyma (acinar atrophy, fibrosis, inflammatory infiltrates).



**Figure 3 Kaplan-Meier curves of complication-free survival of pathophysiologically grouped complications prior to, and following surgical management of chronic pancreatitis in a cohort of 166 patients.**



**Figure 4 Kaplan-Meier curves of complication-free survival characterizing the impact of the type of surgery on occurrence of the new complications of chronic pancreatitis. The log-rank test was used to assess differences between the curves.** A: Peripancreatic complications (Whipple’s pancreatoduodenal resection–red line, other pancreatic resections–blue line, pancreatic drainage operations–green line); B: Pancreatic exocrine insufficiency (Whipple’s pancreatoduodenal resection–red line, other pancreatic resections–blue line, pancreatic drainage operations–green line); C: Pancreatic endocrine insufficiency (pancreatic distal resection–orange line, other pancreatic resections–blue line, pancreatic drainage operations–green line).

**Table 1 Characteristics of the surgically treated patients with chronic pancreatitis**

|  |  |
| --- | --- |
| **Characteristic** | **Patients, *n* = 166** |
| **Age in yr** | 49.8 ± 9.9 |
| **Duration of CP before surgery, median (IQR)** | 1.5 (0.5–3.0) |
| **Male sex, *n* (%)** | 140 (84.3) |
| **Etiology of CP, *n* (%)** |  |
| Alcoholic | 148 (89.2) |
| Other | 18 (10.8) |
| **Predominant indication for surgery, *n* (%)** |  |
| Chronic pain | 112 (67.5) |
| Complications of CP1 | 54 (32.5) |
| Follow-up (yr), median (IQR) | 7.2 (3.8–10.8) |
| **Long-term survival (Kaplan-Meier), (95%CI)** |  |
| 1 yr | 100 |
| 5 yr | 88.2 (83.0–93.5) |
| 10 yr | 70.4 (61.7–79.1) |
| 15 yr | 41.2 (27.4–55.1) |
| Median survival in yr | 13.9 |

Data are presented as mean ± SD, unless otherwise specified.

1In many cases, patients had also more or less intense abdominal pain.

CI: Confidence interval; CP: Chronic pancreatitis; IQR: Interquartile range; SD: Standard deviation.

**Table 2 Surgical treatment of 166 patients with chronic pancreatitis**

|  |  |  |
| --- | --- | --- |
| **Type of surgery** | ***n* (%)** |  |
| **Pancreatic resection** | 60 (36.2) |  |
| Pancreatoduodenal resection (Whipple procedure) |  | 11 |
| DPPHR (Beger or Berne or Frey procedure) |  | 34 |
| Pancreatic distal resection |  | 15 |
| **Pancreatic drainage operation** | 93 (56.0) |  |
| Pancreaticojejunostomy (Partington-Rochelle) |  | 93 |
| **Palliative procedures** | 13 (7.8) |  |
| Biliodigestive anastomosis |  | 11 |
| Gastrointestinal anastomosis |  | 2 |

DPPHR: Duodenum-preserving pancreatic head resection.

**Table 3 Baseline and 15-yr Kaplan-Meier prevalence of complications of chronic pancreatitis in a surgically treated cohort of 166 patients**

|  |  |  |
| --- | --- | --- |
| **Complications**  | **Baseline, *n* (%)** | **15-yr, Kaplan-Meier, %** |
| **Pancreatic duct complications** | 34 | 20.5 | 21.2 |
| ***Pancreatic pseudocysts*** | 18 | 10.8 |  |
| ***Pancreatic fistulas*** | 16 | 9.6 |  |
| *Pancreaticoperitoneal (pancreatic ascites)* | 4 | 2.4 |  |
| *Pancreaticopleural (pancreatic pleural effusion)* | 5 | 3.0 |  |
| *Other (mostly pancreaticocutaneous)* | 6 | 4.2 |  |
| **Peripancreatic complications** | 391 | 23.5 | 35.6 |
| *Bile duct obstruction* | 29 | 17.5 |  |
| *Duodenal obstruction* | 8 | 4.8 |  |
| *Venous thrombosis (splenic or portal vein)* | 5 | 3.0 |  |
| **Pancreatic hemorrhages** | 17 | 10.2 | 10.2 |
| ***Contained pseudoaneurysms*** | 7 | 4.2 |  |
| ***Ruptured pseudoaneurysms into*** | 10 | 6.0 |  |
| *Abdominal cavity* | 2 | 1.2 |  |
| *Gastrointestinal tract* | 6 | 3.6 |  |
| *Pancreatic duct* | 2 | 1.2 |  |
| **Pancreatic exocrine insufficiency–PEI**  | 52 | 31.3 | 66.4 |
| **Pancreatic endocrine insufficiency–T3cDM** | 45 | 27.1 | 47.1 |

1Three patients had two concurrent complications at baseline.

PEI: Pancreatic exocrine insufficiency; T3cDM: Type 3c diabetes mellitus.

**Table 4 Distribution of complications of chronic pancreatitis according to the used type of surgical procedure prior to surgical treatment, and appearance of new complications during follow-up, in 166 surgically treated patients**

|  |  |
| --- | --- |
| **Classification** | **Type of surgical procedure, *n* (%)** |
| **PD resection, *n =* 11** | **DPPHR, *n =* 34** | **Distal resection, *n =* 15** | **Drainage procedure, *n =* 93** | **Palliative procedures, *n =* 13** | **Total, *n =* 166** |
| **Complications, *n* (%)** |  |  |  |  |  |
| **Pancreatic duct complications** | 1 (9.1) | 1 (2.9) | 4 (26.7) | 29 (31.2) | - | 35 (21.1) |
| Preoperative cases | 1 | 1 | 4 | 28 | - | 34 |
| New cases, FU | - | - | - | 1 | - | 1 |
| **Peripancreatic complications** | 6 (54.5) | 9 (26.5) | - | 25 (26.9) | 13 (100)1 | 55 (33.1) |
| Preoperative cases | 6 | 4 | - | 17 | 13 | 42 |
| New cases, FU | - | 5 | - | 8 | - | 13 |
| **Pancreatic hemorrhages** | 1 (9.1) | 1 (2.9) | 9 (60.0) | 6 (6.5) | - | 17 (10.2) |
| Preoperative cases | 1 | 1 | 9 | 6 | - | 17 |
| New cases, FU | - | - | - | - | - | - |
| **PEI** | 8 (72.7) | 15 (44.1) | 5 (33.3) | 46 (49.5) | 9 (69.2) | 83 (50.0) |
| Preoperative cases | 1 | 6 | 3 | 33 | 9 | 52 |
| New cases, FU | 7 | 9 | 2 | 13 | - | 31 |
| **T3cDM** | 3 (27.3) | 12 (35.3) | 8 (53.3) | 39 (41.9) | 11 (84.6) | 73 (44.0) |
| Preoperative cases | 1 | 7 | 2 | 25 | 10 | 45 |
| New cases, FU | 2 | 5 | 6 | 14 | 1 | 28 |

1Three patients had simultaneously two peripancreatic complications. DPPHR: Duodenum-preserving pancreatic head resection; FU: Follow up; PD: Pancreatoduodenal resection; P: Pancreatic; PEI: Pancreatic exocrine insufficiency; T3cDM: Type 3c diabetes mellitus.